GILD Stock Quote - Gilead Sciences Inc Stock News, ResearchWarren Buffett Guru Investors

55.81 (1y: +121%)

Market Cap	84.57 B	P/E(ttm)	31.40
Enterprise Value	90.89 B	P/B	9.00

GILD- NAS (USA)
Gilead Sciences Inc

Currently 1/5

Business Predictability Rank: 1-Star
Back Testing Results:
Average gain of all 1-Star stocks: 1.1% per year.
% of Stocks that are in still loss if held for 10yrs: 45%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies

$55.81

3 Severe Warning Signs 4 Medium Warning Signs 1 Good Sign

Bookmark

Jump to: Guru Trade | Guru Ownership | Insider Trade

Key Ratios

New Key Statistics Module, Z-Score and F-Score

Market Cap $M	84,566	Revenue $M	9,952	Net Margin (%)	26.7	Z-Score	5.7
Enterprise Value $M	90,895	EPS $	1.8	Operating Margin %	41.3	F-Score	7
P/E(ttm))	31.4	Cash Flow Per Share $	4.3	Pre-tax Margin (%)	37.2	Higher ROA y-y	Y
Price/Book	9.0	10-y EBITDA Growth Rate %	0	Quick Ratio	5.0	Cash flow > Earnings	Y
Price/Sales	9.0	5-y EBITDA Growth Rate %	16.3	Current Ratio	1.2	Lower Leverage y-y	Y
Price/Cash Flow	17.4	y-y EBITDA Growth Rate %	9.8	ROA % (ttm)	12.2	Higher Current Ratio y-y	Y
Dividend Yield %	0	Insider Buy (3m)	1	ROE % (ttm)	27.8	Less Shares Outstanding y-y	N
Payout Ratio %	0	Shares Outstanding M	1,522	ROI % (ttm)	17.3	Gross Margin Increase y-y	Y

Gurus Latest Trades with GILD

Please Subscribe to see portfolio changes after the end of the last quarter. Real Time Picks are included for Premium Members only! Plans start from as little as $299/year.

7-Day FREE TRIAL

Select Gurus | Default List of Gurus | All Investors | Mutual Fund Gurus | Hedge Fund Gurus

Number of guru portfolios checked: 51.

Ticker	Date	Action	Impact	Price Range (Average)*	Current Price	Change from Average	Comment	Current Shares
GILD	2012-09-30	Sold Out	-3%	$25.34 - $33.89 ($28.46)	$ 55.81	96%	Sold Out	0
GILD	2012-03-31	Add	1.86%	$21.01 - $28.01 ($22.41)	$ 55.81	149%	Add 553.12%	252,495
GILD	2011-12-31	Reduce	-0.12%	$18.13 - $21.4 ($19.99)	$ 55.81	179%	Reduce -24.28%	38,660
GILD	2011-09-30	Buy	0.49%	$17.67 - $21.61 ($19.97)	$ 55.81	180%	New holding, 51055 sh.	51,055
GILD	2011-06-30	Sold Out	-2.42%	$19.42 - $21.41 ($20.35)	$ 55.81	174%	Sold Out	0
GILD	2010-09-30	Buy	2.46%	$15.92 - $18.28 ($17.1)	$ 55.81	226%	New holding, 407915 sh.	407,915
Real Time Picks are included for Premium Members only!!

*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

Total Records: 6

GILD is held by these Gurus:

Select Gurus | Default List of Gurus | All Investors | Mutual Fund Gurus | Hedge Fund Gurus

Ticker	Guru Name	Portfolio Date*	Current Shares	% of Shares Outstanding	% of Total Assets Managed	Change from Last Holdings
GILD	Mario Gabelli	2013-03-31	27,200	0	0.01	+119.89%
GILD	Jean-Marie Eveillard	2013-03-31	400	0	0
GILD	John Griffin	2013-03-31	8,000,000	0.53	4.9
GILD	Vanguard Health Care Fund	2013-03-31	6,721,600	0.44	1.3	-3.48%
GILD	John Hussman	2013-03-31	558,000	0.04	1	-20.29%
GILD	Joel Greenblatt	2013-03-31	9,784	0	0.02	-70.85%
GILD	John Burbank	2013-03-31	0	0	0	Sold Out
GILD	George Soros	2013-03-31	0	0	0	Sold Out

Most recent portfolio changes are included for Premium Members only!

GILD: Insider Buys/Sells

Click Here for All Insider Trades.

Insider	Position	Date	Trades	Shares	Trade Price ($)	Change (%)	Details
MARTIN JOHN C	Chairman and CEO	2013-05-01	Sell	282,242	$50.17	11.08	view
Alton Gregg H	EVP, Corp & Med Affairs	2013-05-01	Sell	30,000	$50.2	11.02	view
Washington Robin L	SVP, CFO	2013-04-11	Sell	968	$50.2	11.02	view
MARTIN JOHN C	Chairman and CEO	2013-04-01	Sell	282,242	$48.3	15.38	view
Washington Robin L	SVP, CFO	2013-04-01	Sell	13,000	$48.33	15.31	view
Alton Gregg H	EVP, Corp & Med Affairs	2013-04-01	Sell	30,000	$48.37	15.22	view
Washington Robin L	SVP, CFO	2013-03-27	Sell	45,000	$47.07	18.4	view
Washington Robin L	SVP, CFO	2013-03-14	Sell	4,304	$45.85	21.55	view
Washington Robin L	SVP, CFO	2013-03-05	Sell	54,800	$44.28	25.86	view
MARTIN JOHN C	Chairman and CEO	2013-03-01	Sell	282,242	$43.14	29.18	view

Press Releases about GILD :

Gilead anuncia los resultados completos de fase 2 de 24... 07 Mar 2013
Gilead veröffentlicht Gesamtergebnisse der 24-wöchigen... 07 Mar 2013
Gilead ha comunicato i risultati completi a 24 settimane... 07 Mar 2013
Gilead kondigt de volledige fase 2 resultaten na 24 weken... 07 Mar 2013
Gilead Announces Full 24-Week Phase 2 Results for Once-Daily... 05 Mar 2013

Quarterly/Annual Reports about GILD:

10-Q - GILEAD SCIENCES INC (0000882095)...: (10-Q) 06 Nov 2012
10-Q - GILEAD SCIENCES INC (0000882095)...: (10-Q) 04 May 2012
10-K - GILEAD SCIENCES INC (0000882095)...: (10-K) 23 Feb 2012
10-Q - GILEAD SCIENCES INC (0000882095)...: (10-Q) 04 Nov 2011
10-Q - GILEAD SCIENCES INC (0000882095)...: (10-Q) 05 Aug 2011

News about GILD:

symbol=GILD Articles On GuruFocus.com

Weekly CEO Sells Highlight: Activision Blizzard, Nielsen Holdings NV, Gilead Sciences, Autodesk Apr 08 2013

WEEKLY CFO SELLS HIGHLIGHT: ANIK, GILD, PETM, NKE, ADBE Mar 31 2013

Stevie Cohen On Board with Real Estate Betting, Despite SEC Probe Jan 18 2013

Weekly Top Insider Sells: NOW, FB, GILD, and ISRG Nov 26 2012

Weekly Top Insider Sells： AAPL, GILD, BMRN, and PCLN Nov 19 2012

Wedgewood Partners' David Rolfe Comments on Gilead Sciences Nov 12 2012

Wedgewood Partners Third Quarter 2012 Review and Outlook Nov 12 2012

Edward Owens’ Vanguard Health Care Fund Does More Shedding than Adding in Third Quarter Nov 01 2012

Weekly CFO Sells Highlight: ASGN, COF, AKRX, MCRS, GILD, ROP, PLL Sep 24 2012

FDA's Truvada Approval Seals Gilead's Leading Position Jul 20 2012

Add Notes, Comments or Ask Questions

Please log in first

Comments

No comment yet

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names

Home About Jobs Advertise Site Map Term of Use Privacy Policy RSS Email Alerts Affiliate Program FAQ Contact Us
Disclaimers: GuruFocus.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The gurus may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.

FocusBar

Home

Premium Membership

Value Screens

Model Portfolios

Guru Stocks

Market Valuation

By Country

Articles

Submit Articles